• It's like CRISPR Therapeutics, but solely dedicated to developing gene therapies for Duchenne Muscular Dystrophy.
• Imagine an early-stage Gilead Sciences, aiming to bring transformative gene therapies to Duchenne Muscular Dystrophy patients.

• SGT-001: A gene transfer candidate currently in Phase I/II clinical trials for treating Duchenne muscular dystrophy.
• SGT-003: A next-generation gene transfer candidate designed for the treatment of Duchenne muscular dystrophy.
• Dual Gene Expression Technology: A platform technology that enables packaging multiple transgenes into a single vector for gene therapy.
• Novel Capsid Platform: A platform technology focused on developing new capsids for improved gene transfer.

Solid Biosciences Inc. (SLDB) primarily operates in the research and development phase for therapies related to Duchenne Muscular Dystrophy. Their lead product candidates are in clinical trials, meaning they are not yet selling commercial products directly to individuals (patients) or hospitals.

Based on the provided information, Solid Biosciences' major customer is another company with whom they have a collaboration and license agreement.

• Ultragenyx Pharmaceutical Inc. (Symbol: RARE)

Ultragenyx Pharmaceutical Inc. is collaborating with and licensing technology from Solid Biosciences to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy, making them a key partner and, in essence, a primary "customer" for Solid Biosciences' intellectual property and development efforts at this stage.

Bo Cumbo, President and CEO

Bo Cumbo was appointed President and Chief Executive Officer of Solid Biosciences in December 2022. Prior to this role, he served as President and CEO of AavantiBio, a company acquired by Solid Biosciences in September 2022. The acquisition of AavantiBio by Solid Biosciences was notably anchored by a group of institutional investors, including private equity firms such as Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, and Vestal Point Capital. Following the acquisition, Adam Koppel, a managing director at Bain Capital Life Sciences, joined Solid's board of directors. Ian Smith, a member of Solid Biosciences' board, also acts as a senior advisor to Bain Capital Life Sciences.

Kevin Tan, Chief Financial Officer

Kevin Tan was appointed Chief Financial Officer of Solid Biosciences in January 2023. Before joining Solid Biosciences, Mr. Tan served as CFO at Selecta Biosciences. His prior experience also includes a role as Treasurer at Sarepta Therapeutics. Earlier in his career, Mr. Tan had an extensive background in financial services, most recently as a Senior Portfolio Manager at CPP Investments, where he managed billions in capital across public markets.

Jessie Hanrahan, Ph.D., Chief Regulatory & Preclinical Operations Officer

Jessie Hanrahan serves as the Chief Regulatory & Preclinical Operations Officer at Solid Biosciences.

Ty Howton, Chief Operating Officer

Ty Howton is the Chief Operating Officer at Solid Biosciences. He previously held the position of Chief Administrative Officer for the company.

Dr. Gabriel Brooks, M.D., Chief Medical Officer

Dr. Gabriel Brooks serves as the Chief Medical Officer for Solid Biosciences.

Solid Biosciences Inc. (SLDB) faces several significant risks inherent to its position as a clinical-stage biotechnology company focused on gene therapies, particularly for Duchenne Muscular Dystrophy (DMD).

Key Risks to Solid Biosciences (SLDB)

1. Clinical Trial Failure and Safety Concerns: The most substantial risk to Solid Biosciences is the potential for its lead gene therapy candidates, SGT-001 and SGT-003, to fail in ongoing or future clinical trials. As a development-stage company, Solid Biosciences' entire valuation and future prospects are predicated on the successful translation of early-stage data into marketable products. Failure to demonstrate sufficient efficacy or an acceptable safety profile in later-stage trials, or the inability to replicate positive interim results, would be a critical setback. Gene therapies for DMD are particularly challenging due to factors such as gene size, the multitude of mutations causing the disease, the efficacy of genetic structure delivery, and significant concerns regarding patient immune responses to both the transgene and the viral vector, which can undermine treatment benefits or lead to serious adverse events, including fatalities.
2. Regulatory Approval Uncertainty: Even if Solid Biosciences' product candidates achieve positive clinical trial outcomes, there is no guarantee that they will receive marketing approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA). The regulatory pathway for novel gene therapies, especially for a complex disease like DMD, is intricate and can be unpredictable. Delays, disruptions, or unfavorable decisions from regulatory agencies, including the denial of accelerated approval pathways that the company is pursuing for SGT-003, could significantly prolong development timelines and impact the company's ability to commercialize its therapies.
3. Intense Competition and Single-Disease Focus in DMD: Solid Biosciences operates in a highly competitive landscape for DMD therapies. Numerous other companies are actively developing gene therapies and other treatments for Duchenne muscular dystrophy. While Solid Biosciences has initiated programs in other neuromuscular and cardiac diseases, its primary focus and the bulk of its pipeline are concentrated on DMD. The emergence of a more effective, safer, or more competitively priced therapy from a competitor, or an evolving understanding of DMD pathogenesis that renders their approach less favorable, could severely limit the market potential and commercial success of Solid Biosciences' candidates, even if they are approved.

Expected Drivers of Future Revenue Growth for Solid Biosciences (SLDB) Over the Next 2-3 Years:

1. Advancement of SGT-003 for Duchenne Muscular Dystrophy (DMD): Solid Biosciences' lead gene therapy candidate, SGT-003, is a primary driver. The company is actively progressing SGT-003 through clinical development, having recently provided positive interim clinical data from its Phase 1/2 INSPIRE DUCHENNE trial, showing robust microdystrophin expression and a favorable safety profile in 40 participants. Key near-term milestones include ongoing discussions with the U.S. Food and Drug Administration (FDA) in the first half of 2026 to align on a potential accelerated approval pathway, with an update expected mid-year 2026. Additionally, Solid Biosciences has initiated the Phase 3 IMPACT DUCHENNE trial outside the U.S., with the first participant dosing expected in the first quarter of 2026. Positive regulatory outcomes and continued clinical progress with SGT-003 could lead to significant milestone payments from partners and enhance the company's valuation, paving the way for eventual commercialization.
2. Expansion and Monetization of the AAV-SLB101 Capsid Platform: Solid Biosciences' proprietary next-generation capsid, AAV-SLB101 (used in SGT-003), represents a valuable platform technology with broad application potential. The company has already executed over 50 agreements, including licenses, with various corporations, institutions, and academic labs for the use of AAV-SLB101. Continued expansion of these licensing agreements and potential future sublicensing or collaboration opportunities based on this technology are expected to generate revenue through upfront payments, milestone fees, and potentially royalties.
3. Progression of Additional Pipeline Programs: Beyond DMD, Solid Biosciences is advancing other gene therapy candidates for rare neuromuscular and cardiac diseases. These include SGT-212 for Friedreich's Ataxia (FA), which dosed its first participant in the Phase 1b FALCON trial in January 2026, with initial data anticipated in the second half of 2026. Furthermore, SGT-501 for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) has activated clinical trial sites for its Phase 1b ARTEMIS trial, with participant screening underway. Positive clinical data and further advancement of these programs within the next 2-3 years could attract new partnerships, trigger additional development milestone payments, and diversify the company's potential revenue streams.

Share Issuance

• Solid Biosciences announced a private placement in March 2026, expecting to raise approximately $240 million from the sale of 14,973,257 common shares and pre-funded warrants for up to 27,807,482 shares.
• In February 2025, the company priced an underwritten offering, which was expected to generate approximately $200 million in gross proceeds through the sale of 35,739,810 shares of common stock and 13,888,340 pre-funded warrants.

Inbound Investments

• In October 2020, Ultragenyx Pharmaceutical Inc. made a $40 million equity investment in Solid Biosciences, purchasing roughly 7.8 million shares at a premium of nearly 50% over the stock's closing price.
• The collaboration with Ultragenyx also includes potential cumulative milestone payments of up to $255 million per product, along with tiered royalties on worldwide net sales, upon the achievement of specified milestone events.
• The $240 million private placement in March 2026 saw participation from both existing and new institutional investors, including prominent names such as Perceptive Advisors, Bain Capital Life Sciences, and RA Capital Management.

Capital Expenditures

• Capital expenditures for Solid Biosciences were reported at -$792,000 in the last 12 months, contributing to a free cash flow of -$133.17 million.
• The company's trailing twelve months (TTM) Capital Expenditures percentage is 0%.